Table 1.

Patient demographics, cefepime levels, and pharmacokinetic parameters following a 3-min infusion of 2 g of cefepime to intensive care unit patientsa

PatientAPACHE scorecCLCR (ml/min)C12 h(μg/ml)t1/2β (h)AUC (μg · h/ml)CL (ml/min)MRT (h)VSS (liter)
1b 2454.019.75.6 (0.3)690 (22)48 (2)7.6 (0.4)22.0 (1.0)
210133.82.61.8 (0.1)239 (12)140 (7)2.0 (0.1)17.0 (1.4)
316103.25.72.9 (0.1)423 (10)79 (2)3.9 (0.1)18.4 (0.6)
4b 1567.29.64.7 (0.3)396 (13)84 (3)6.2 (0.4)31.4 (1.6)
511157.21.11.5 (0.1)226 (9)148 (6)1.7 (0.1)15.0 (0.9)
69153.61.62.3 (0.1)199 (12)167 (10)2.6 (0.1)26.4 (2.4)
79135.62.12.5 (0.1)241 (9)138 (5)3.0 (0.1)24.6 (1.3)
8b 1463.610.04.0 (0.2)467 (14)71 (2)5.3 (0.2)22.8 (1.1)
915187.21.62.2 (0.1)257 (8)130 (4)2.6 (0.1)20.2 (0.9)
1011117.61.11.9 (0.1)285 (11)117 (4)2.3 (0.1)16.2 (0.8)
11897.26.33.5 (0.2)337 (12)99 (4)4.4 (0.2)26.3 (1.7)
128141.01.62.3 (0.1)194 (9)172 (8)2.9 (0.1)29.8 (2.0)
131379.88.53.8 (0.1)424 (10)79 (2)5.1 (0.2)24.0 (0.9)
Mediand 10.5134.71.92.52491342.822.1
Meand 11.0130.63.23.02831273.121.8
SDd 2.832.02.61.285331.15.1
  • a CLCR, creatinine clearance; C12 h, cefepime concentration at 12 h postdose; t1/2β, elimination half-life; AUC, area under the plasma cefepime concentration-time curve; CL, cefepime clearance; MRT, mean residence time; VSS, apparent volume at steady state. Values shown are estimates, and their standard errors are shown in parentheses.

  • b Patient nonevaluable.

  • c APACHE score at time of initial cefepime dose.

  • d Only data for evaluable patients are included in these statistical results.